Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,588.82
(
-0.54%
)
US TECH 100
23,594.80
(
-0.85%
)
Dow Jones
45,903.91
(
-0.69%
)
Brent Oil
104.85
(
-1.62%
)
Bitcoin
69,764.59
(
-2.07%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 182628

Monday, 12/01/2014 9:04:12 AM

Monday, December 01, 2014 9:04:12 AM

Post# of 257259
MNTA’s Necuparanib receives FDA Fast Track designation for pancreatic cancer:

http://finance.yahoo.com/news/momenta-pharmaceuticals-necuparanib-receives-fast-131500946.html

Necuparanib also has an FDA Orphan Drug indication for the same indication (#msg-102765888). The phase-1 data from the ongoing phase-1/2 trial testing Gemzar+Abraxane ± Necuparanib were reported in detail at MNTA’s R&D Day in October (#msg-107057169).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now